Xbrane Biopharma AB - Involved in the pharmaceutical megatrend

I haven’t really followed this, but big gainers and losers are always interesting.

So, a 343Mkr rights issue is being proposed for a company whose market cap fell 75% today (at the time of writing) to a market cap of 57Mkr.

The rights issue will only take place after the Extraordinary General Meeting (EGM) in late February, meaning the subscription rights will be detached only after that. Presumably, bad news regarding the sales outlook was also shared today, and while additional financing was expected to be needed, it was even more than the market anticipated—quite a slaughter.

1 Like